1
|
Zheng L, Zhang FJ. Adult rhabdomyosarcoma combined with acute myeloid leukemia: A case report. World J Clin Cases 2024; 12:582-586. [PMID: 38322472 PMCID: PMC10841940 DOI: 10.12998/wjcc.v12.i3.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 12/17/2023] [Accepted: 01/04/2024] [Indexed: 01/18/2024] Open
Abstract
BACKGROUND Rhabdomyosarcoma is a tumor of mesenchymal origin. Secondary leukemia is a complication of previous transformation to other hematologic disorders or is a treatment-related acute myeloid leukemia secondary to cytotoxic chemotherapy or radiation therapy for other malignancies. CASE SUMMARY We present the case of a 36-year-old female patient who was diagnosed with rhabdomyosarcoma and acute myeloid leukemia. Further disease progression was observed after multiline chemotherapy. Eventually, the patient suffered cerebral hemorrhage, which resulted in death. CONCLUSION The incidence of rhabdomyosarcoma in adults is extremely low, and secondary leukemia caused by rhabdomyosarcoma is even rarer. Secondary leukemia has a very poor prognosis and a low overall survival rate.
Collapse
Affiliation(s)
- Lu Zheng
- Department of Hematology, Lishui Municipal Central Hospital, Lishui 323000, Zhejiang Province, China
| | - Fen-Juan Zhang
- Department of Hematology, Lishui Municipal Central Hospital, Lishui 323000, Zhejiang Province, China
| |
Collapse
|
2
|
Du Y, Wang Y, Li Q, Chang X, Zhang H, Xiao M, Xing S. Risk and outcome of acute myeloid leukaemia among survivors of primary diffuse large B-cell lymphoma: a retrospective observational study based on SEER database. BMJ Open 2022; 12:e061699. [PMID: 36581968 PMCID: PMC9438207 DOI: 10.1136/bmjopen-2022-061699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
OBJECTIVES Survivors of diffuse large B-cell lymphoma (DLBCL) are at an increased risk of developing second primary malignancies. However, the risk of secondary acute myeloid leukaemia (sAML) has not been previously described in detail, and the outcomes of patients with sAML are also undiscovered compared with their de novo counterparts (de novo acute myeloid leukaemia, dnAML). DESIGN This study is a retrospective database study. SETTING AND PARTICIPANTS A total of 70 280 patients with primary DLBCL, diagnosed between 2000 and 2016, were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Another cohort with dnAML matching with sAML was also obtained from SEER database. RESULTS The standardised incidence ratio was 6.23 (95% CI: 5.50 to 7.03) for sAML among survivors of DLBCL. The estimated cumulative incidence of sAML was 0.61% 15 years after the diagnosis of DLBCL. Patients aged 60-74 years were more likely to have sAML than those <60 years (subdistribution HR (sHR)=1.417; 95% CI: 1.087 to 1.850), whereas patients aged ≥75 years were less likely to have sAML (sHR=0.648; 95% CI: 0.452 to 0.930). Patients with advanced-stage DLBCL were more prone to sAML than those with early-stage disease (sHR=1.307; 95% CI: 1.012 to 1.690). There was a significant difference of survival between patients with dnAML and those with sAML (HR=1.25; 95% CI: 1.01 to 1.53). CONCLUSIONS The risk of developing sAML after DLBCL is substantial. Patients aged 60-74 years and with advanced-stage are more prone to sAML. And, compared with their dnAML counterparts, patients with sAML have a worse prognosis.
Collapse
Affiliation(s)
- Yu Du
- Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Ying Wang
- Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qinlu Li
- Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xiaona Chang
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Heng Zhang
- Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Min Xiao
- Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Shugang Xing
- Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
3
|
Prusila REI, Sorigue M, Jauhiainen J, Mercadal S, Postila A, Salmi P, Tanhua T, Tikkanen S, Kakko S, Kuitunen H, Pollari M, Nystrand I, Kuusisto MEL, Vasala K, Jantunen E, Korkeila E, Karihtala P, Sancho J, Turpeenniemi‐Hujanen T, Kuittinen O. Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era. Br J Haematol 2019; 187:364-371. [DOI: 10.1111/bjh.16090] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Accepted: 05/21/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Roosa E. I. Prusila
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
| | - Marc Sorigue
- Department of Haematology ICO‐Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras Badalona Spain
| | - Jyrki Jauhiainen
- Department of Applied Physics University of Eastern Finland Kuopio Finland
| | - Santiago Mercadal
- Department of Haematology ICO‐Hospital Duran i Reynals, Hospitalet de Llobregat Barcelona Spain
| | - Aleksi Postila
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
| | - Petteri Salmi
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
| | - Taru Tanhua
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
| | - Susanna Tikkanen
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
| | - Sakari Kakko
- Department of Haematology Oulu University Hospital Oulu Finland
| | - Hanne Kuitunen
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
| | - Marjukka Pollari
- Department of Oncology Tampere University Hospital Tampere Finland
| | - Ilja Nystrand
- Department of Oncology Turku University Hospital Turku Finland
| | - Milla E. L. Kuusisto
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
- Siunsote – Hospital District of North Carelia Joensuu Finland
| | - Kaija Vasala
- Department of Oncology and Radiotherapy Central Finland Central Hospital Jyväskylä Finland
| | - Esa Jantunen
- Siunsote – Hospital District of North Carelia Joensuu Finland
- Department of Medicine Kuopio University Hospital Kuopio Finland
- Institute of Clinical Medicine, Faculty of Health Medicine University of Eastern Finland Kuopio Finland
| | - Eija Korkeila
- Department of Oncology Turku University Hospital Turku Finland
| | - Peeter Karihtala
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
| | - Juan‐Manuel Sancho
- Department of Haematology ICO‐Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras Badalona Spain
| | - Taina Turpeenniemi‐Hujanen
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
| | - Outi Kuittinen
- Medical Research Centre and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland
- Institute of Clinical Medicine, Faculty of Health Medicine University of Eastern Finland Kuopio Finland
- Department of Oncology Kuopio University Hospital Kuopio Finland
| |
Collapse
|
4
|
Liang Y, Wang Y, Xiao M, Hao Y, Zhang Y, Li S. Tumor necrosis factor receptor 2 may promote the proliferation and drug resistance of Kapras299 and L428 lymphoma cells via the AKT and WNT/β-catenin signaling pathways. Oncol Lett 2018; 15:8847-8852. [PMID: 29928327 DOI: 10.3892/ol.2018.8396] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Accepted: 10/18/2017] [Indexed: 02/06/2023] Open
Abstract
Circulating soluble tumor necrosis factor receptor 2 (sTNFR2) has been associated with a relatively poor prognosis in various types of lymphoma. However, the specific role of TNFR2 expression in lymphoma cells remains uncharacterized. In the present study, TNFR2 expression was quantified in the Hodgkin lymphoma cell line, L428, and the anaplastic large-cell lymphoma cell line, Karpas299, using RT-PCR and western blot analyses. Karpas299 cells exhibited higher TNFR2 expression than L428 cells. Proliferation and drug resistance experiments demonstrated that Karpas299 cells also possessed a greater proliferative ability and resistance to adriamycin (ADM) than L428 cells, with 50% inhibitory concentrations (IC50) of 1.423±0.24 µmol/l for Karpas299 cells, compared with 0.728±0.15 µmol/l for L428 cells (P<0.05). The knockdown of TNFR2 in Karpas299 cells significantly reduced their proliferative ability; when treated with ADM, the cell inhibition rate increased from 49.34±5.42% to 74.13±6.81% (P<0.05). The upregulation of TNFR2 in L428 cells significantly increased their proliferative ability; when treated with ADM, the cell inhibition rate decreased from 47.03±5.25% to 28.71±4.90% (P<0.05). Investigation of the underlying molecular mechanism indicated that the upregulation of TNFR2 expression in L428 cells increased the expression of β-catenin and the phosphorylation of AKT. In L428 cells overexpressing TNFR2, the β-catenin blocker, DKK1, or the AKT inhibitor, LY294002, abrogated the increase in proliferation induced by TNFR2 and increased cell inhibition rate upon treatment with ADM. In summary, the present study demonstrated that TNFR2 promoted the proliferative and drug resistance abilities of lymphoma cells via the AKT and WNT/β-catenin signaling pathways. This may provide the experimental basis for the further study of TNFR2 activity in lymphoma cells and warrant its investigation as a therapeutic target for lymphoma.
Collapse
Affiliation(s)
- Yanyan Liang
- Department of Hematology, First People's Hospital of Jining City, Jining, Shandong 257335, P.R. China
| | - Yu Wang
- Department of Medicine 11, People's Hospital of Xintai City, Tai'an, Shandong 271200, P.R. China
| | - Meng Xiao
- Department of Hematology, First People's Hospital of Jining City, Jining, Shandong 257335, P.R. China
| | - Yunliang Hao
- Department of Hematology, First People's Hospital of Jining City, Jining, Shandong 257335, P.R. China
| | - Yongtian Zhang
- Department of Hematology, First People's Hospital of Jining City, Jining, Shandong 257335, P.R. China
| | - Shumei Li
- Department of Hematology, First People's Hospital of Jining City, Jining, Shandong 257335, P.R. China
| |
Collapse
|
5
|
Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. Bone Marrow Transplant 2017; 52:969-976. [PMID: 28368379 DOI: 10.1038/bmt.2017.52] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Revised: 12/26/2016] [Accepted: 01/29/2017] [Indexed: 01/22/2023]
Abstract
Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n=9963) or allogeneic (n=3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P<0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P=0.04) or secondary malignancies (P<0.001) and receiving cord blood stem cell (P=0.03) or involved field radiotherapy (P=0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.
Collapse
|
6
|
Son MY, Deng CX, Hoeijmarkers JH, Rebel VI, Hasty P. A mechanism for 1,4-Benzoquinone-induced genotoxicity. Oncotarget 2016; 7:46433-46447. [PMID: 27340773 PMCID: PMC5216808 DOI: 10.18632/oncotarget.10184] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 05/22/2016] [Indexed: 12/30/2022] Open
Abstract
Benzene is a common environmental toxin and its metabolite, 1-4-Benzoquinone (BQ) causes hematopoietic cancers like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). BQ has not been comprehensively assessed for its impact on genome maintenance, limiting our understanding of the true health risks associated with benzene exposure and our ability to identify people with increased sensitivity to this genotoxin. Here we analyze the impact BQ exposure has on wild type and DNA repair-defective mouse embryonic stem (ES) cells and wild type human cells. We find that double strand break (DSB) repair and replication fork maintenance pathways including homologous recombination (HR) and Fanconi anemia (FA) suppress BQ toxicity. BQ-induced damage efficiently stalls replication forks, yet poorly induces ATR/DNA-PKCS responses. Furthermore, the pattern of BQ-induced γH2AX and 53BP1foci is consistent with the formation of poly(ADP-ribose) polymerase 1 (PARP1)-stabilized regressed replication forks. At a biochemical level, BQ inhibited topoisomerase 1 (topo1)-mediated DNA ligation and nicking in vitro; thus providing mechanism for the cellular phenotype. These data are consistent with a model that proposes BQ interferes with type I topoisomerase's ability to maintain replication fork restart and progression leading to chromosomal instability that has the potential to cause hematopoietic cancers like MDS and AML.
Collapse
Affiliation(s)
- Mi Young Son
- Department of Molecular Medicine and Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
| | - Chu-Xia Deng
- Faculty of Health Sciences, University of Macau, Macau SAR China
| | - Jan H. Hoeijmarkers
- Department of Genetics, Cancer Genomics Netherlands, Erasmus MC, The Netherlands
| | - Vivienne I. Rebel
- Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
- The Cancer Therapy Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
- The Barshop Center of Aging, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
- Greehey Children's Cancer Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
- Current address: BioAffinity, San Antonio, Texas, USA
| | - Paul Hasty
- Department of Molecular Medicine and Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
- The Cancer Therapy Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
- The Barshop Center of Aging, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
| |
Collapse
|